1691249-45-2

Basic information

• Product Name: Zanubrutinib
• Synonyms: Zanubrutinib
• CAS NO: 1691249-45-2
• Molecular Formula: C₂₇H₂₉N₅O₃
• Molecular Weight: 471.55086
• EINECS: -0
• Product Categories: API
• Mol File: 1691249-45-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 713.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: 15.35±0.40(Predicted)
• CAS DataBase Reference: Zanubrutinib(CAS DataBase Reference)
• NIST Chemistry Reference: Zanubrutinib(1691249-45-2)
• EPA Substance Registry System: Zanubrutinib(1691249-45-2)

Safety Data

• Hazardous Substances Data: 1691249-45-2(Hazardous Substances Data)

Usage

Uses

Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma.

Upstream product

• 814-68-6 acryloyl chloride 
• 330792-70-6 5-amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile 
• 79-10-7 acrylic acid 
• 1633350-06-7 7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant articles and documents

Preparation method of BTK inhibitor and intermediate thereof

The invention relates to a preparation method of (S)-7-(1-acryloyl piperidine-4-yl)-2-(4-phenoxy phenyl)-4, 5, 6, 7-tetrahydropyrazolo[1, 5-a]pyrimidine-3-formamide and an intermediate thereof.

Novel method for synthesizing Zanubrutinib

The invention relates to a novel method for synthesizing Zanubrutinib. The synthetic route provided by the invention has the characteristics of few reaction steps, high yield, good operability, simpleprocess and the like. The method does not involve low-temperature reactions, and can effectively realize industrial large-scale production.

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies. The discovery of a more selective on-target covalent BTK inhibitor is of high value. Herein, we disclose the discovery and preclinical characterization of a potent, selective, and irreversible BTK inhibitor as our clinical candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds. Compound BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.